Risks For Pharma Industry Remain As BIO Shifts Course On BIOSECURE Act

 
• By Sarah Karlin-Smith

Trade group’s break from WuXi Apptec allows BIO to reset its lobbying approach under its new CEO but doesn’t negate the business and supply chain disruptions that biopharma would feel from the proposed legislation.

picture of American and Chinese flags slightly overlapping.
• Source: Shutterstock

More from Legislation

More from Pink Sheet